Clinical trial of efficacy and safety, prospective, multicenter, randomized, double-blind, placebo-controlled, with subcutaneous immunotherapy in patients with rhinitis/rhinocojunctivitis with or without mild to moderate asthma sensitized to grasses and/or
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: INMUNOTEK, SL
- Phase: III
- Execution start: 18/12/2020
- End of execution: 30/09/2022
- IP: JOSE FERNANDO FLORIDO LOPEZ